Table 2.
Survivin inhibitors currently in phase I/II clinical trials
| Mechanism of action | Compound | Clinical Trials | Indication |
|---|---|---|---|
| Antisense oligonucleotides | LY2181308 | Phase I | AML |
| Phase II | AML, NSCLC (+docetaxel) and HRPC (+docetaxel) | ||
| Terameprecol (EM-1421) | Phase I | Leukemia | |
| Phase II | AML, NSCLC (+/- docetaxel), HRPC (+docetaxel) | ||
| Transcriptional Repressors | Phase I | Solid tumors | |
| YM155 | Phase II | NSCLC(+carboplatin/paclitaxel), HRPC (+docetaxel), HER2 negative breast cancer (+docetaxel) Melanoma |
|
| Vaccine Therapy With Dendritic Cells - Transfected With hTERT-, Survivin- and Tumor Cell Derived mRNA + ex Vivo T Cell Expansion and Reinfusion | Phase I/II | Melanoma | |
| Multipeptide vaccine: PSMA and Survivin | Phase I/II | Prostate cancer | |
| Survivin peptide vaccine | Phase I/II | Solid tumors | |
| Multipeptide Vaccine: telomerase and survivin | Phase I | Breast cancer | |
| Immunotherapy | Multipeptide vaccine: MART-1, keyhole limpet hemocyanin, recombinant MAGE-3.1, survivin and autologous dendritic cells | Phase I/II | Melanoma |
| Multipeptide vaccine: MART-1, gp100 and survivin antigens + GM-CSF +/- IL2 | Phase I | Melanoma | |
| Stem Cell Transplant, Chemotherapy, and Biological Therapy (CMV N495 peptide, CMV pp65 peptide, hTERT I540/R572Y/D988Y multipeptide vaccine, pneumococcal polyvalent vaccine, survivin Sur1M2 peptide vaccine) | Phase I/II | Multiple Myeloma | |
| Dendritic Cells Transfected With Survivin, hTERT and p53 mRNA | Phase I/II | Breast Cancer or Malignant Melanoma | |
| Survivin and telomerase peptide-pulsed dendritic cells | Phase I/II | Renal Cell Carcinoma | |
AML, Acute myeloid leukemia; CMV, cytomegalovirus; GM-CSF, granulocyte-macrophage colony stimulating factor; HRPC, hormone-refractory prostate cancer; hTERT, human telomerase reverse transcriptase; IL-2, interleukin-2; MAGE, melanoma-associated antigen NSCLC, non-small cell lung cancer; PSMA, prostate-specific membrane antigen.